Antitrust Antitrust

US Senate committee advances bill to improve drug-pricing transparency; Wicker questions FTC's 'catch-all hook'

A US Senate committee cleared a bill that would prevent unfair and deceptive practices related to pharmacy benefit-management services for prescription drugs in a 19-9 vote, but not before a Republican expressed concern about handing more power to the Federal Trade Commission.
In an executive session, the US Senate Commerce,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US

Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News